Compare iShares iBoxx $ High Yield Corporate Bond ETF (HYG) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ High Yield Corporate Bond ETF vs BIO-TECHNE Corp — how do they compare? iShares iBoxx $ High Yield Corporate Bond ETF trades at $77.17 (market cap $17.89B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: iShares iBoxx $ High Yield Corporate Bond ETF is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while iShares iBoxx $ High Yield Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ High Yield Corporate Bond ETF for 59 Days and BIO-TECHNE Corp for 63 Days on average.
| HYG | TECH | |
|---|---|---|
Market Cap | $17.89B | $11.36B |
Volume | 44,866,592 | 5,390,331 |
Sector | Fixed Income | Health |
52-Week High | $81.28 | $72.61 |
52-Week Low | $76.90 | $43.31 |
Typical Hold Time | 59 Days | 63 Days |
Enterprise Value | — | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HYG (iShares iBoxx $ High Yield Corporate Bond ETF) trades at $77.115, down 0.08% with a bearish technical signal from moving averages. The fund has shown unusual options activity recently amid a challenging bond market environment where Treasury yields have reached multi-year highs. Recent dividend payments of $0.34-$0.44 per share provide income support, but the overall technical picture remains weak with significant selling pressure.
The outlook for HYG remains challenged by rising interest rates and bond market volatility. While the fund offers attractive yield income through regular dividends, the bearish technical momentum and elevated Treasury yields create headwinds for price appreciation. Key risks include further rate hikes and credit spread widening in the high-yield bond market.
Bio-Techne (TECH) trades at $72.47, down 0.08% on the day, near its 52-week high of $72.70 (Defense World, 2026-09-28). The stock shows a bullish technical trend with strong moving average signals. Recent shareholder approval of the acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23) is a key catalyst. Q2 2026 earnings beat expectations with EPS of $0.52 versus $0.519 expected, though net income margin has declined from 25.09% in 2023 to 14.96% in 2026.
The pending acquisition offers a near-term upside to the current price, but high valuation ratios (P/E of 62.46, P/S of 9.36) pose a risk if the deal faces regulatory hurdles. Analyst consensus is mixed with 46% Buy and 54% Hold ratings. The stock presents a favorable risk-reward for investors seeking a takeover arbitrage opportunity, with the primary risk being deal failure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
